Den Europæiske Union - dansk - EMA (European Medicines Agency)

intervet international bv - levende deletion-mutant streptococcus equi stamme tw928 - immunologier til hovdyr - heste - for vaccination af heste mod streptococcus equi at reducere kliniske symptomer og forekomst af lymfeknuder-node bylder. immunitetens begyndelse: påbegyndelsen af ​​immunitet er etableret som to uger efter basisvaccination. varighed af immunitet: varigheden af ​​immunitet er op til tre måneder. vaccinen er beregnet til anvendelse i heste, hvor der er tydeligt identificeret en risiko for streptococcus equi-infektion på grund af kontakt med heste fra områder, hvor dette patogen er kendt for at være til stede, e. stalde med heste, der rejser til shows eller konkurrencer i sådanne områder, eller stalde, der henter eller har livery heste fra sådanne områder.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastiske midler - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi er indiceret til behandling af voksne patienter med lokalt fremskreden eller metastatisk nsclc efter forudgående kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq som monoterapi er indiceret til behandling af voksne patienter med lokalt fremskreden eller metastatisk nsclc efter forudgående kemoterapi. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

sanofi b.v. - vandetanib - thyroid neoplasms - antineoplastiske og immunomodulerende midler - caprelsa er indiceret til behandling af aggressiv og symptomatisk medulær thyreoideacancer (mtc) hos patienter med uopløselig lokalt avanceret eller metastatisk sygdom. caprelsa er indiceret hos voksne, børn og unge i alderen 5 år og ældre. for patienter, hos hvem re-arrangeret-under-transfektion(ret) mutation ikke kendes, eller er negativ, og en eventuel lavere ydelse skal tages i betragtning, inden individuel behandling beslutning.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

elanco gmbh - lotilaner, milbemycin oxime - endektocider - hunde - for use in dogs with, or at risk from, mixed infestations/infections of ticks, fleas, gastrointestinal nematodes, heartworm and/or lungworm.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - leukæmi, myelogen, kronisk, bcr-abl positiv - antineoplastiske midler - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vetoquinol s.a. - emodepside, toltrazuril - antiparasitiske produkter, insekticider og repellenter - hunde - for hunde, når de er blandet parasitære infektioner med rundorme og coccidia af følgende arter, der er mistanke om eller påvist:rundorme (nematoder)toxocara canis (mature adult, umodne voksne, l4);uncinaria stenocephala (mature adult);ancylostoma caninum (mature adult). coccidiaisospora ohioensis kompleks;isospora canis. procox er effektiv mod replikationen af ​​isospora og også mod udslæt af oocytter. selv om behandling vil reducere infektionens spredning, vil den ikke være effektiv mod de kliniske tegn på infektion hos allerede inficerede dyr.